Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta …
J Liu, X Qiao, M Wu, H Wang, H Luo, H Zhang… - Frontiers in …, 2023 - frontiersin.org
Introduction Recent studies have indicated that the dosage of LMWH in patients with specific
weights may be controversial. Therefore, we conducted a meta-analysis to explore an …
weights may be controversial. Therefore, we conducted a meta-analysis to explore an …
Anticoagulant therapy in COVID‐19: A narrative review
Z Mohseni Afshar, A Tavakoli Pirzaman… - Clinical and …, 2023 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …
Venous thromboembolism and obesity: moving toward a better understanding of the population-attributable risk
KA Martin, NA Zakai - Thrombosis and Haemostasis, 2024 - thieme-connect.com
The prevalence of obesity is staggering, with recent estimates of more than 1.9 billion
overweight and 650 million obese adults worldwide. 1 Venous thromboembolism (VTE) is …
overweight and 650 million obese adults worldwide. 1 Venous thromboembolism (VTE) is …
Direct oral anticoagulants and the risk of adverse clinical outcomes among patients with different body weight categories: a large hospital-based study
EM Nwanosike, HA Merchant, W Sunter… - European Journal of …, 2024 - Springer
Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity
JD Sperry, A Loeb, MJ Smith, TB Brighton… - Journal of Thrombosis …, 2024 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …
Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications
Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …
Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial
Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …
The 5 most frequently asked questions about factor Xa inhibitors
Direct oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent
years. However, in some special clinical situations, the appropriate use of these …
years. However, in some special clinical situations, the appropriate use of these …
A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches
EM Nwanosike, W Sunter, MA Ansari… - American Journal of …, 2023 - Springer
Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …
[PDF][PDF] A real-world exploration into clinical outcomes of direct oral anticoagulant (DOAC) dosing regimens in morbidly obese patients using data-driven approaches
EM Nwanosike, W Sunter, MA Ansari, HA Merchant… - pure.hud.ac.uk
The clinical outcomes of direct oral anticoagulant (DOACs) dosage regimens in morbid
obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …
obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …